A recent case report demonstrated a clinical response to the second-generation ALK inhibitor alectinib in a patient with de novo NEPC harboring an ALK p.F1174C activating mutation, suggesting that targeting ALK could be relevant in selected patients with prostate cancer (16). This evidence concerns the gene ALK and Familial prostate cancer.